Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Facial Cutaneous Mucormycosis in a Full-term Infant

Facial Cutaneous Mucormycosis in a Full-term Infant CLINICAL NOTE Facial Cutaneous Mucormycosis in a Full-term Infant Sandeep P. Dave, MD; Richard J. Vivero, AB; Soham Roy, MD, FAAP ucormycosis is a rare and potentially fatal fungal infection that most commonly affects the immunocompromised population. Although originally described by Pal- 1(p573) tauf in 1885 (D. G. Finn as cited by Vessely et al and A. M. Marchevsky as 2(p1607) M cited by Oh and Notrica ), it was not until 1955 that Harris (as cited by Ves- 1(p573) sely et al ) reported the first case of a mucormycosis survivor. In recent years, the number of immunosuppressed patients has increased partly owing to the widespread implementation of or- gan transplantation and the increasing prevalence of human immunodeficiency virus infection. Consequently, the incidence of mucormycosis has also increased, especially in pediatric patients. In the setting of immunocompromise, a high index of suspicion is required to accurately diagnose and treat this potentially lethal infection in a timely fashion. To our knowledge, we report the first case of facial cutaneous mucormycosis in an infant, who also represents the first reported neonate or infant to survive a cutaneous mucormycosis infection of the head and neck. After an uncomplicated liver, partial gas- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Otolaryngology - Head & Neck Surgery American Medical Association

Facial Cutaneous Mucormycosis in a Full-term Infant

Download PDF
4 pages

Loading next page...
 
/lp/american-medical-association/facial-cutaneous-mucormycosis-in-a-full-term-infant-LdffrtTNAU

References (9)

Publisher
American Medical Association
Copyright
Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6181
eISSN
2168-619X
DOI
10.1001/archoto.2007.48
pmid
18283166
Publisher site
See Article on Publisher Site

Abstract

CLINICAL NOTE Facial Cutaneous Mucormycosis in a Full-term Infant Sandeep P. Dave, MD; Richard J. Vivero, AB; Soham Roy, MD, FAAP ucormycosis is a rare and potentially fatal fungal infection that most commonly affects the immunocompromised population. Although originally described by Pal- 1(p573) tauf in 1885 (D. G. Finn as cited by Vessely et al and A. M. Marchevsky as 2(p1607) M cited by Oh and Notrica ), it was not until 1955 that Harris (as cited by Ves- 1(p573) sely et al ) reported the first case of a mucormycosis survivor. In recent years, the number of immunosuppressed patients has increased partly owing to the widespread implementation of or- gan transplantation and the increasing prevalence of human immunodeficiency virus infection. Consequently, the incidence of mucormycosis has also increased, especially in pediatric patients. In the setting of immunocompromise, a high index of suspicion is required to accurately diagnose and treat this potentially lethal infection in a timely fashion. To our knowledge, we report the first case of facial cutaneous mucormycosis in an infant, who also represents the first reported neonate or infant to survive a cutaneous mucormycosis infection of the head and neck. After an uncomplicated liver, partial gas-

Journal

JAMA Otolaryngology - Head & Neck Surgery – American Medical Association

Published: Feb 1, 2008

There are no references for this article.